XORTX Therapeutics Files 6-K, Incorporates Exhibits
Ticker: XRTX · Form: 6-K · Filed: Oct 23, 2025 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
XORTX files 6-K, incorporates exhibits into F-3. Standard corporate update.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 23, 2025, reporting for the month of October 2025. The filing incorporates by reference Exhibits 99.2, 99.3, 99.4, and 99.5 into its Registration Statement on Form F-3 (File No. 333-269429). The company is based in Vancouver, Canada, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates ongoing regulatory and corporate activities for XORTX Therapeutics, potentially related to its F-3 registration statement which is used for issuing securities.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates previously filed exhibits into an existing registration statement, with no new material financial or operational information disclosed.
Key Numbers
- 20251023 — Filing Date (Date the Form 6-K was filed with the SEC.)
- October 2025 — Reporting Period (The month for which the Form 6-K is reporting.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Filer of the Form 6-K
- 333-269429 (other) — File number for the Registration Statement on Form F-3
- 001-40858 (other) — Commission File Number for XORTX Therapeutics Inc.
FAQ
What is the purpose of incorporating exhibits into the Form F-3 registration statement?
Incorporating exhibits into a Form F-3 registration statement allows those documents to be considered part of the registration statement, providing additional information to potential investors about the company and its securities.
What type of company is XORTX Therapeutics Inc. classified as?
XORTX Therapeutics Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
What specific exhibits are being incorporated by reference in this filing?
Exhibits 99.2, 99.3, 99.4, and 99.5 are being incorporated by reference into the Registration Statement on Form F-3.
Where is XORTX Therapeutics Inc. primarily located?
XORTX Therapeutics Inc. has its principal executive offices located at 3710 – 33rd Street NW Calgary, Alberta T2L 2M1, Canada, and its business and mail address is Suite 2400 - 745 Thurlow Street, Vancouver, BC V6E 0C5.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2025-10-22 21:24:34
Filing Documents
- tm2529022d2_6k.htm (6-K) — 11KB
- tm2529022d2_ex99-1.htm (EX-99.1) — 11KB
- tm2529022d2_ex99-2.htm (EX-99.2) — 48KB
- tm2529022d2_ex99-3.htm (EX-99.3) — 190KB
- tm2529022d2_ex99-4.htm (EX-99.4) — 25KB
- tm2529022d2_ex99-5.htm (EX-99.5) — 78KB
- image_001.jpg (GRAPHIC) — 5KB
- image_002.jpg (GRAPHIC) — 3KB
- 0001104659-25-101635.txt ( ) — 376KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date:October 22, 2025 By: /s/ Allen Davidoff Name:Allen Davidoff Title:President and Chief Executive Officer Form 6-K Exhibit Index Exhibit Number Document Description 99.1 Press Release of the Registrant, dated October 21, 2025 99.2 Placement Agency Agreement between D. Boral Capital LLC and XORTX Therapeutics Inc., dated October 21, 2025 99.3 Form of Securities Purchase Agreement, between XORTX Therapeutics Inc. and Purchaser, dated October 21, 2025 99.4 Form of Lock-Up Agreement 99.5 Form of Pre-Funded Common Share Purchase Warrant